News releases
Apitope to present at the “Therapeutic & Preventative Vaccines for Autoimmune Diseases: Scientific & Commercial Opportunities” symposium.
9 JANUARY 2011, 2.45PM (PST) Bristol, UK / Hasselt, Belgium – 7th January 2011: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, is pleased to announce that Dr. Keith Martin, CEO, will provide an update on Apitope (antigen processing independent epitope autoimmune vaccines) at the symposium on “Therapeutic & Preventative Vaccines for Autoimmune Diseases: Scientific & Commercial Opportunities”, sponsored by the Juvenile Diabetes Research Foundation and Fast Forward, LLC.
Read more >>
or download (PDF)
Apitope appoints Dr Martin Sims as Research Director
Bristol, England / Hasselt, Belgium – 5 January 2011: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announces today that Dr. Martin Sims will join the Senior Management team as Research Director with immediate effect. Martin will be responsible for Apitope’s research operations, working closely with the Chief Scientific Officer (CSO), Professor David Wraith, to guide the company’s overall scientific strategy.
Read more >>
or download (PDF)
Apitope appoints Hayley French as Commercial Director
Bristol, England / Hasselt, Belgium – 01 November 2010: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announces today that Hayley French will join its management team as Commercial Director with immediate effect. Hayley will be responsible for maximising the potential of Apitope’s innovative technology platform.
Read more >>
or download (PDF)
Apitope grows operations with move to St Brandon's House, Bristol, UK
Bristol, England / Hasselt, Belgium – 01 October 2010: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announced today that it has relocated its UK subsidiary HQ to larger premises at St Brandon’s House, 29 Great George Street, Bristol, BS1 5QT, UK, as a result of significant growth in Apitope’s business and staff.
Read more >>
or download (PDF)
Apitope Starts New Clinical Trial of its Investigational Multiple Sclerosis Treatment
Bristol, UK / Hasselt, Belgium – 18 May 2010: Apitope, the European biotech company developing therapeutic peptides to treat autoimmune and allergic diseases, today announced the start of its second Phase I clinical trial of ATX-MS-1467, in patients with Multiple Sclerosis (MS).
Read more >>
or download (PDF)
Apitope to present at BioEquity Europe Conference
Apitope International N.V., the autoimmune peptide therapy company, announces today that Dr. Keith Martin, CEO, will give an overview of the Company’s business at ‘BioEquity Europe 2010’. The presentation will be at the Swissôtel Zurich, Switzerland at 15.30 (CET) on Wednesday, 19 May 2010.
Read more >>
or download (PDF)
Apitope presenting at the Peptide Conference
Apitope International N.V., the autoimmune peptide therapy company, announced today that Dr. Keith Martin, CEO, will give an overview of the Company’s business at ‘The Peptide Conference’. The presentation will be at The Wellcome Trust Conference Centre, Cambridge, UK at 4pm (BST) on Tuesday, 30th March 2010.
The presentation will provide an insight into how Apitope designs and develops therapeutic peptides for revolutionary treatment of autoimmune diseases and allergies.
Read more >>
or download (PDF)
Apitope hires Dr. Graham Roberts as Development Director for Therapeutics
Apitope International N.V., the autoimmune peptide therapy company, announced today the appointment of Dr. Graham Roberts as Development Director for Therapeutics. Among his responsibilities at Apitope, Dr Roberts will have overall responsibility for Apitope’s R&D activities with an initial focus on the ATXMS-1467 project. In January, Apitope signed a development and commercialization deal with Merck Serono to develop ATX-MS-1467, a targeted approach to treat multiple sclerosis.
Dr. Roberts joins Apitope from SRA GCD Ltd (formerly, Constella Group Ltd), which he joined in 2004 and was promoted to Global VP of Regulatory Affairs & Strategic Drug Development Services in early 2009. more (PDF)
Dr. Keith Martin, CEO of Apitope, Receives the AstraZeneca, Business Development Professional of the Year Award 2008 at the PLG UK Annual Awards
Apitope International NV, is proud to announce that Dr. Keith Martin, CEO of Apitope, has received the AstraZeneca, Business Development Professional of the Year Award 2008. David Brennan, CEO of AstraZeneca PLC, gave the award at the Pharmaceutical Licensing Group (PLG) Annual Awards Dinner 2009.
The deal, negotiated by Dr. Martin, granted Merck Serono exclusive, worldwide rights to develop and commercialise Apitope's ATX-MS-1467 to treat multiple sclerosis. ATX-MS-1467 is a novel peptide-based therapeutic derived from Apitope’s proprietary technology platform. The deal was announced in January. more (PDF)
